A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia
Journal of Drugs in Dermatology · 2023
DOI: 10.36849/jdd.7340 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Drugs in Dermatology, 2023. Verfasst von Jordan Wang und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Dermatologic Agents, Hyperpigmentation, Melanosis.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Wang, J., Fabi, S., Robinson, D., Bajaj, S., Geronemus, R., Bell, M., & Widgerow, A. (2023). A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7340
Vancouver
Wang J, Fabi S, Robinson D, Bajaj S, Geronemus R, Bell M, et al. A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia. Journal of Drugs in Dermatology. 2023. doi:10.36849/jdd.7340
BibTeX
@article{Wang2023,
author = {Wang, Jordan and Fabi, Sabrina and Robinson, Deanne and Bajaj, Shirin and Geronemus, Roy and Bell, Michaela and Widgerow, Alan},
title = {A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia},
journal = {Journal of Drugs in Dermatology},
year = {2023},
doi = {10.36849/jdd.7340}
}
EUVIMED